With the bladder cancer market projected to grow in the upcoming years, the development of new immunotherapies like STING Agonists allow for a breakthrough in the fight against bladder cancer. Written by Omar Aly, Sarah Bortel, Jakob Heinz, and Andrés Melendez.

Image for post
Image for post

Bladder Cancer Overview

Bladder cancer is the most expensive cancer per the National Cancer Institute, being ranked first in lifetime treatment costs and is the sixth most frequently diagnosed cancer. Estimates indicate that by the year 2023, the United States bladder cancer market will be close to six billion dollars. In 2018, Datamonitor Healthcare estimated 546,400 incident cases of bladder cancer globally…


Drug development has historically been a long, expensive, and difficult process. How will the use of artificial intelligence impact the future of this industry? Written by Charlie Almoney, Morgan Kofsky, Jake Pearson, and Jenny Zwerling

Image for post
Image for post

In 2019, the total estimated cost to research and develop a novel prescription medicine was $2.6 billion per drug. This figure has increased from $800 million in 2003. Additionally, the rate of success of drugs in clinical trials is 12%, a decrease by half over the same time period1. While costs have risen, the success rate of drug development has been driven down, displaying a…


We know MRD detection is feasible and widely employed for hematological cancers… but what does the future hold for solid tumor MRD technologies? Written by Alex Kernagis, Rayna Saldanha, Claire Liddy and Bryan Kaplan.

Image for post
Image for post

A New Frontier

The niche space of minimal residual disease testing is quickly growing within the world of biotech due to great strides in sequencing and biopsy technology development over the last decade. Minimal residual disease (MRD) is a term used to describe detectable residual fragments of cancer in patients who have had cancer treatment with a curative intent such as surgery or chemotherapy. …


Image for post
Image for post

Description: JHU’s newest student-run healthcare and life-sciences consulting group

An Exciting New Chapter

Cobalt Consulting Group was founded in 2020 to bridge the rapidly budding business community with the prestigious biomedical atmosphere of Johns Hopkins!

Cobalt is entirely operated by students at Johns Hopkins University, helping to advise innovative companies within the thriving industries of life-sciences and healthcare — historically consulting companies and startups that have brought in more than $200 million in grants and total venture funding to date.

Nearly half of our team comes with experience from the JHU Biomedical Engineering Department, the top BME program in the…

Cobalt Consulting Group

The newest student-run healthcare and life-sciences consulting group at the Johns Hopkins University

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store